enGene Holdings Inc. (ENGNW)

NASDAQ: ENGNW · Real-Time Price · USD · Warrants
0.6750
-0.0050 (-0.74%)
Sep 8, 2025, 4:00 PM - Market closed
-0.74%
Market Cap277.50M
Revenue (ttm)n/a
Net Income (ttm)-79.88M
Shares Out 51.11M
EPS (ttm)-1.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,831
Open0.6800
Previous Close0.6800
Day's Range0.6700 - 0.7200
52-Week Range0.5100 - 2.7400
Beta-0.41
Analystsn/a
Price Targetn/a
Earnings DateMar 13, 2025

About ENGNW

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ronald H. Cooper
Employees 57
Stock Exchange NASDAQ
Ticker Symbol ENGNW
Full Company Profile

News

There is no news available yet.